AI assistant
Sending…
Celldex Therapeutics, Inc. — Director's Dealing 2013
Jun 20, 2013
31801_dirs_2013-06-20_01810347-bfee-4787-90d4-fa5935796574.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2013-06-19
Reporting Person: Elston George (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2013-06-19 | Common Stock | A | 2000 | — | Acquired | 10000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2013-06-19 | Non-Qualified Stock Option (right to buy) | $15.20 | A | 2000 | Acquired | 2023-06-19 | Common Stock (2000) | Direct |
Footnotes
F1: On June 19, 2013, the Company awarded 2,000 shares of the Company common stock as an annual equity grant in the form of restricted stock awards under the Celldex Therapeutics, Inc. 2008 Stock Option and Incentive Plan, subject to time-based forfeiture restrictions.
F2: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan.
F3: Such option vests in four equal quarterly installments beginning September 19, 2013.
More from Celldex Therapeutics, Inc.
Interim / Quarterly Report
2026
May 7
Regulatory Filings
2026
May 7
Major Shareholding Notification
2026
May 6
Major Shareholding Notification
2026
Apr 29
Annual Report
2026
Apr 29
Proxy Solicitation & Information Statement
2026
Apr 29
Regulatory Filings
2026
Apr 2
Regulatory Filings
2026
Apr 2
Regulatory Filings
2026
Apr 1
Major Shareholding Notification
2026
Mar 26